Celadon Pharmaceuticals PLC Departure of Chief Financial Officer
September 30 2024 - 2:05AM
RNS Regulatory News
RNS Number : 1242G
Celadon Pharmaceuticals PLC
30 September 2024
Celadon Pharmaceuticals
Plc
("Celadon", the "Group" or the
"Company")
Departure of Chief Financial
Officer
London, 30 September 2024 - The
Board of Celadon Pharmaceuticals Plc (AIM: CEL) announces that Mr
Jonathan Turner, Chief Financial Officer, will leave his position
on the Board on 27 December 2024.
The Board would like to express its
thanks and gratitude to Mr Turner for his contribution to the
Company and wishes him well in his future endeavours.
The Company will be starting the
search for Mr Turner's successor imminently and will provide a
further update when a new candidate has been appointed.
Enquiries:
|
|
Celadon Pharmaceuticals Plc
|
|
James Short
Jonathan Turner
|
Via Sodali & Co
|
Canaccord Genuity Limited (Nominated Adviser and
Broker)
|
|
Bobbie Hilliam / Andrew
Potts
|
+44 (0)20 7523 8000
|
|
|
Global Investment Strategy UK Limited (Joint
Broker)
James Sheehan
|
+44 (0)20 7048 9400
|
Sodali & Co
|
|
Elly Williamson / Sam Austrums /
Nick Johnson
|
+44 (0)20 7250 1446
|
|
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a
UK-based pharmaceutical company focused on
the development, production and sale of breakthrough cannabis-based
medicines. Its primary focus is on
improving quality of life for chronic pain sufferers, as well as
exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP
approved and comprises indoor hydroponic cultivation, proprietary
GMP extraction and an analytical and R&D laboratory. Celadon's
Home Office licence allows for the commercial supply of its
pharmaceutical-grade cannabis product. The Group owns an approved
clinical trial using cannabis-based medicinal products to treat
chronic pain in the UK. Celadon also has a minority interest in
early-stage biopharma Kingdom Therapeutics, which is developing a
licensed cannabinoid medicine to treat children with Autism
Spectrum Disorder.
For further information please visit
our website www.celadonpharma.com
This announcement contains inside
information for the purposes of article 7 of the Market Abuse
Regulation (EU) 596/2014 as amended by regulation 11 of the Market
Abuse (Amendment) (EU Exit) Regulations 2019/310. With the
publication of this announcement, this information is now
considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BOAZKLFLZKLLBBB
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Oct 2024 to Nov 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Nov 2023 to Nov 2024